BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 24519981)

  • 41. Prion protein and Alzheimer disease.
    Kellett KA; Hooper NM
    Prion; 2009; 3(4):190-4. PubMed ID: 19887909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death.
    Kudo W; Lee HP; Zou WQ; Wang X; Perry G; Zhu X; Smith MA; Petersen RB; Lee HG
    Hum Mol Genet; 2012 Mar; 21(5):1138-44. PubMed ID: 22100763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein.
    Rösener NS; Gremer L; Reinartz E; König A; Brener O; Heise H; Hoyer W; Neudecker P; Willbold D
    J Biol Chem; 2018 Oct; 293(41):15748-15764. PubMed ID: 30131337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Binding between Prion Protein and Aβ Oligomers Contributes to the Pathogenesis of Alzheimer's Disease.
    Kong C; Xie H; Gao Z; Shao M; Li H; Shi R; Cai L; Gao S; Sun T; Li C
    Virol Sin; 2019 Oct; 34(5):475-488. PubMed ID: 31093882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Memory impairment in transgenic Alzheimer mice requires cellular prion protein.
    Gimbel DA; Nygaard HB; Coffey EE; Gunther EC; Laurén J; Gimbel ZA; Strittmatter SM
    J Neurosci; 2010 May; 30(18):6367-74. PubMed ID: 20445063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition.
    Williams TL; Choi JK; Surewicz K; Surewicz WK
    ACS Chem Neurosci; 2015 Dec; 6(12):1972-80. PubMed ID: 26466138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease.
    Debatin L; Streffer J; Geissen M; Matschke J; Aguzzi A; Glatzel M
    Neurodegener Dis; 2008; 5(6):347-54. PubMed ID: 18349519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activation of zebrafish Src family kinases by the prion protein is an amyloid-β-sensitive signal that prevents the endocytosis and degradation of E-cadherin/β-catenin complexes in vivo.
    Sempou E; Biasini E; Pinzón-Olejua A; Harris DA; Málaga-Trillo E
    Mol Neurodegener; 2016 Feb; 11():18. PubMed ID: 26860872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Domains of STIP1 responsible for regulating PrPC-dependent amyloid-β oligomer toxicity.
    Maciejewski A; Ostapchenko VG; Beraldo FH; Prado VF; Prado MA; Choy WY
    Biochem J; 2016 Jul; 473(14):2119-30. PubMed ID: 27208175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage.
    Whitehouse IJ; Miners JS; Glennon EB; Kehoe PG; Love S; Kellett KA; Hooper NM
    PLoS One; 2013; 8(4):e59554. PubMed ID: 23577068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier.
    Pflanzner T; Petsch B; André-Dohmen B; Müller-Schiffmann A; Tschickardt S; Weggen S; Stitz L; Korth C; Pietrzik CU
    J Cereb Blood Flow Metab; 2012 Apr; 32(4):628-32. PubMed ID: 22293988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease.
    Baker-Nigh A; Vahedi S; Davis EG; Weintraub S; Bigio EH; Klein WL; Geula C
    Brain; 2015 Jun; 138(Pt 6):1722-37. PubMed ID: 25732182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prion Protein as a Toxic Acceptor of Amyloid-β Oligomers.
    Purro SA; Nicoll AJ; Collinge J
    Biol Psychiatry; 2018 Feb; 83(4):358-368. PubMed ID: 29331212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
    Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
    ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-β oligomer toxicity.
    Ostapchenko VG; Beraldo FH; Mohammad AH; Xie YF; Hirata PH; Magalhaes AC; Lamour G; Li H; Maciejewski A; Belrose JC; Teixeira BL; Fahnestock M; Ferreira ST; Cashman NR; Hajj GN; Jackson MF; Choy WY; MacDonald JF; Martins VR; Prado VF; Prado MA
    J Neurosci; 2013 Oct; 33(42):16552-64. PubMed ID: 24133259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein.
    Barry AE; Klyubin I; Mc Donald JM; Mably AJ; Farrell MA; Scott M; Walsh DM; Rowan MJ
    J Neurosci; 2011 May; 31(20):7259-63. PubMed ID: 21593310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
    Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
    J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.